Fig 2.
Kaplan-Meier estimates of (A, B, C) progression-free and (D, E, F) overall survival outcomes in (A, D) intent-to-treat, (B, E) MET-positive, and (C, F) MET-negative populations. HR, hazard ratio.
Kaplan-Meier estimates of (A, B, C) progression-free and (D, E, F) overall survival outcomes in (A, D) intent-to-treat, (B, E) MET-positive, and (C, F) MET-negative populations. HR, hazard ratio.